NURIX THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
NURIX THERAPEUTICS, INC. (NRIX) reported Payments to Acquire Debt Securities, Available-for-sale of $246.33 million for the 12-month period ending 2023-11-30, per its 10-K filed 2024-02-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2024-02-15
- NURIX THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $246.33M, a 2.91% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $239.37M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|
| 2023-11-30 | $246.33M 10-K · filed 2024-02-15 |
| 2022-11-30 | $239.37M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |